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Abstract 
Background: Reprimo (RPRM), a highly glycosylated protein, is a new downstream effector of p53‑induced cell 
cycle arrest at the G2/M checkpoint, and a putative tumor suppressor gene frequently silenced via methylation of its 
promoter region in several malignances. The aim of this study was to characterize the epigenetic inactivation and its 
biological function in BC cell lines.
Methods: The correlation between RPRM methylation and loss of mRNA expression was assessed in six breast cancer 
cell lines by methylation specific PCR (MSP), 5′‑Aza‑2′‑deoxycytidine treatment and RT‑PCR assays. MDA‑MB‑231 cells 
were chosen to investigate the phenotypic effect of RPRM in cell proliferation, cell cycle, cell death, cell migration and 
invasion.
Results: In the cancer methylome system (CMS) (web‑based system for visualizing and analyzing genome‑wide 
methylation data of human cancers), the CpG island region of RPRM (1.1 kb) was hypermethylated in breast cancer 
compared to normal breast tissue; more interesting still was that ERα(+) tumors showed higher methylation intensity 
than ERα(−). Downregulation of RPRM mRNA by methylation was confirmed in MDA‑MB‑231 and BT‑20 cell lines. In 
addition, overexpression of RPRM in MDA‑MB‑231 cells resulted in decreased rates of cell migration, wound healing 
and invasion in vitro. However, RPRM overexpression did not alter cell viability, phosphatidylserine (PS) translocation or 
G2/M cell cycle transition.
Conclusion: Taken together, these data suggest that RPRM is involved in decreased cell migration and invasion 
in vitro, acting as a potential tumor suppressor gene in the MDA‑MB‑231 cell line.
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Background
Breast cancer (BC) is the second most common cancer 
in the world and by far the most frequent cancer among 
women. Approximately, 1.67 million new cancer cases 
were diagnosed in 2012 (25  % of all cancers), being the 
second cause of cancer death in developed regions 
(198,000 deaths, 15.4 %) [1].
Loss of proliferation regulation and the activation 
of invasion and metastasis are considered hallmarks 
in many cancer types, including BC. These processes 
are tightly regulated within normal cells. A deregula-
tion in proliferation may occur by several mechanisms, 
including direct expression of growth factor ligands and 
receptors by cancer cells or by induction of surrounding 
normal cells, which permits an uncontrolled proliferation 
of tumor cells. At this point, the role of tumor suppres-
sor genes that limit growth and proliferation in cancer is 
important [2].
Cell migration plays a central role in a wide variety of 
biological phenomena in both normal physiology and 
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pathophysiology. In a tumor setting, cell migration and 
invasion are the processes that allow malignant cells to 
change their position within tissue or between organs, 
penetrating tissue barriers such as the basement mem-
brane, infiltrating the underlying interstitial tissue and 
spreading to the metastatic sites [3].
The associated cancer cells typically develop many 
alterations in morphology as well as in the cell–cell 
attachment and extracellular matrix to obtain the ability 
to dissociate intracellular adhesions and become motile. 
This process is usually driven by complex regulatory 
signaling cascades that temporarily and/or permanently 
alter the expression of several genes that reorganize the 
cytoskeletal network [2, 4, 5].
In 2000, Ohki et  al. [6] identified a new gene called 
Reprimo (latin for repress), a potential new gene 
p53-dependent tumor suppressor by using differential 
display polymerase chain reaction (PCR) in x-ray-irradi-
ated mouse embryonic fibroblasts.
Reprimo (RPRM) is located at 2q23 and encodes a 
highly glycosylated protein that shows four bands (16, 21, 
23 and 40  kDa) found predominantly in the cytoplasm 
[6]. Nevertheless, in silico gene ontology analysis of its 
amino acid sequence show that RPRM is an integral com-
ponent of cell membrane (URL: http://www.uniprot.org/
uniprot/Q9NS64). Overexpression of RPRM by adeno-
virus transfection induces G2 arrest by inhibiting both 
Cdc2 activity and nuclear translocation of Cdc2-cyclin B1 
complex in mouse embryonic fibroblast, acting as a sup-
pressor of cell cycle progression. Cyclin B1, a key compo-
nent in the control of cell cycle progression from G2 to 
M phase, has been implicated in tumorigenesis and the 
development of malignancy. Overexpression of cyclin B1 
promotes cell invasive growth and extravasation through 
the capillary endothelium [7]. Therefore, RPRM acts as 
mediator of cell cycle transition, blocking nuclear transi-
tion of Cdc2-Cyclin B1 complex [6]. RPRM may repress 
cyclin B1-Cdc2 activity, promoting cell cycle arrest at the 
G2/M checkpoint and/or suppressing metastatic poten-
tial, exerting a tumor suppressive activity [7].
RPRM promoter methylation has been reported in 
several tumor cell lines and tumors including pancreas, 
head and neck, prostate, liver, gastric, renal and pituitary 
[8–16]. In gastric cancer, RPRM methylation has been 
detected frequently in plasma, promising to become a 
biomarker of the early stage of progression [13]. Further-
more, in esophageal cancer RPRM promoter methylation 
is significantly lower in chemoradiotherapy responders 
than in non-responders [17], and is predictive of a poor 
prognosis in pancreatic ductal carcinoma [10].
Nevertheless, in BC there have been no reports about 
whether RPRM mRNA levels are altered by promoter 
methylation and whether act as a repressive mechanism 
of mRNA expression, or about the functional significance 
of the ectopic expression of RPRM in the MDA-MB-231 
cell line. Therefore, we decided characterize the epige-
netic inactivation and its biological function of RPRM in 
BC cell lines.
Results
Reprimo is differentially methylated between BC 
and normal control sample tissues
The cancer methylome system (CMS) website uses a 
computational analysis to calculate the average inten-
sity of RPRM CpG island methylation (Start–End: 
154042600–154043700, length: 1.1  kb, Chromosome 
2) between BC (77) and normal control samples (10) 
(Fig.  1a). The calculated methylation intensity was 
higher in the BC group than in the normal control group 
(Fig. 1b; P < 0.001). Moreover, we correlated the methyla-
tion data with clinic-pathological features, but there were 
no significant differences with any characteristic (data 
not shown). Nevertheless, when BC cases were classified 
into two groups: estrogen receptor positive [ERα(+)] and 
estrogen receptor negative [ERα(−)], we found higher 
methylation intensity in the ERα(+) group (Fig.  1c; 
P  <  0.001). Unfortunately, we could not classify the BC 
tissues into other different molecular subtypes, such as 
Luminal A, Luminal B, Her2 and Basal-like, because data 
of the protein expression of Her2+ and Ki67 were incom-
plete. Based on these results, we decided to characterize 
the epigenetic inactivation and its biological function of 
RPRM in BC cell lines.
Reprimo transcript is downregulated in BC cell lines 
by promoter methylation
To determine the methylation (M) or unmethylated (U) 
status of RPRM promoter, methylation specific poly-
merase chain reaction (MSP) technique was performed. 
The flanked region by primer in 5′-promoter region was 
described in previous reports [8, 18]. The primers were 
tested using 100 % methylated DNA and non-methylated 
DNA before to perform the experiment in cell lines (data 
not shown).
RPRM promoter was methylated in 3/5 (MDA-
MB-231, BT-20 and HCC-1954) of the BC cell lines ana-
lyzed (Fig. 2a). Lost or repressed mRNA expression was 
found in 2/5 (MDA-MB-231 and BT-20) of BC cell lines 
(Fig. 2b). To validate MSP results, we performed a qMSP 
analysis, which revealed promoter methylation in MDA-
MB-231 and BT-20, the same cell lines with a repressed 
RPRM expression (data not shown). After 5′Aza-dC 
treatment, RPRM mRNA expression in MDA-MB-231 
and BT-20 was restored (Fig.  2b). Therefore, we con-
cluded that the transcriptional silencing of RPRM due to 
its promoter methylation in BC.
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Reprimo overexpression suppresses cell migration 
and invasiveness in MDA‑MB‑231
MDA-MB-231 cells were transiently transfected either 
with pCMV6-empty or with pCMV containing the 
full-length cDNA of RPRM gene (pCMV-RPRM). 
MDA-MB-231 cells transfected with pCMV6-RPRM 
(MDA-MB-231-RPRM cells) showed an increase in 
mRNA and protein levels of RPRM, compared to 
pCMV6-empty (MDA-MB-231-pCMV6 cells) (Fig.  3a). 
We tested whether RPRM could alter cell migration and 
invasion by wound healing assay and assays based in 
boyden chamber with or without matrigel matrix. Results 
in transwell migration assays showed a decrease of MDA-
MB-231-RPRM cells migration in about 64.3  % (35.7  % 
of migrated cells) compared to MDA-MB-231-pCMV6 
(Fig. 3b; P< 0.0001). To verify these results, we performed 
a wound-healing assay. On this regard, we found that 48 h 
post-scratch, the wound was completely closed in MDA-
MB-231-pCMV6 cells, while in MDA-MB-231-RPRM 
cells the wound remained open (Fig.  3c). To study the 
invasiveness potential of these treated cells, we perform 
an invasion assay using a Boyden chamber coated with 
matrigel. We found that effectively MDA-MB-231-RPRM 
cells migrated 51  % less than MDA-MB-231-pCMV6 
cells (Fig. 3d; P < 0.0001). In summary, transfected cells 
with RPRM-containing vector (MDA-MB-231-RPRM) 
exhibited significantly lower cell migration and invasion 
rate than those transfected with empty vector (MDA-
MB-231-pCMV6), confirming for first time that RPRM 
regulates cell migration and invasion in cancer cells, par-
ticularly in BC cells.
Reprimo overexpression failed to induce cell death and cell 
cycle arrest in MDA‑MB‑231 BC cells
There were no statistical differences in cell viability 
between cells expressing either a control vector (MDA-
MB-231-pCMV6) or RPRM (MDA-MB-231-RPRM) 
(Fig.  4a). To determine the functional consequences of 
RPRM overexpression in regard to programmed cell 
death, an Annexin V (AV)/propidium iodide (PI) staining 
assay was performed in MDA-MB-231 cells at 48 h post-
transfection. Overexpression of RPRM slightly increased 
apoptosis and cell death, but these differences were not 
significant in compared with control-transfected cells 
(Fig.  4b). Flow cytometry analyses were grouped into 
three types of cell stages according to the Nomenclature 
Committee on Cell Death (2012): live cells (AV−/PI−), 
apoptotic cells (AV+/PI−) and death cells (AV+/PI+, 
Fig. 1 Differential methylation in RPRM CpG island between breast cancer and normal control samples. a Methylation intensity pre‑calculated 
showing as a red gradient heatmap for RPRM CpG Island. At the top part of the figure; in green, shown CpG Island. In black, shown the gene body 
(from 153.992.097 to 154.093.568; Chromosome 2). The black arrow marks the start transcription site (TSS). The region analyzed corresponds to the 
CpG Island from 154.042.600 to 154.043.700 pb (length: 1.1 kb). The cases studied were ten normal breast (top) and 77 primary tumors (below). b 
Methylation intensity in BC was higher than normal control samples. c. Within BC group, ERα(+) group showed higher methylation intensity than 
ERα(−). The Mann–Whitney test was used for each analysis. The error bars indicate standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001
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and AV−/PI+). The average percentage for apoptotic 
cells was 4.0 % for RPRM and 2.5 % for control cells. The 
average percentage for death cells was 6.8  % for RPRM 
and 3.7 % for control cells. In summary, in terms of apop-
totic cells and death cells, we confirmed that cell viability 
was not significantly decreased in MDA-MB-231-RPRM 
compared with MDA-MB-231-pCMV6.
Cells were synchronized by serum deprivation for 
cell cycle profiles; however, there were no changes in 
the percentages of cells in the G2/M phase between 
MDA-MB-231-pCMV6 and MDA-MB-231-RPRM cells 
(Fig.  4c).  Therefore,  RPRM does not have a significant 
effect to alter G2/M in MDA-MB-231 cells.
Discussion
Reprimo is a potential p53-dependent tumor suppressor, 
located at 2q23 and encodes a highly glycosylated protein, 
located predominantly in the cytoplasm. It is believed to 
regulate the activity of the Cdc2-cyclin B1 complex by 
interfering with an as yet unknown checkpoint G2/M 
mechanism operating in the cytoplasm [6]. Several stud-
ies have shown that tumor suppressor genes that partici-
pate in cell cycle arrest are frequently inactivated through 
aberrant methylation in human malignances [19]. In this 
regard, RPRM promoter methylation has been found in 
several human cancers, including pancreas [8, 10, 20], 
head and neck [9], esophagus [17, 21], prostate [11, 22], 
lung [23], kidney [16], pituitary [14] and gastric [13, 
15, 24]. There have been no reports regarding methyla-
tion status or functional studies in BC. Using the CMS 
platform [25], we analyzed the methylation status of the 
RPRM CpG island region (1.1 kb) in BC tissues, finding 
hypermethylation in cancer tissue but not in normal con-
trol samples. Moreover, methylation intensity was higher 
in ERα(+) than ERα(−) in the BC group, suggesting that 
RPRM methylation is linked to ER status. Similarly, Malik 
et al. proposed a repression of RPRM gene transcription 
mediated by a tripartite interaction between ERα, histone 
deacetylase 7 (HDAC7), and FoxA1 [26]. We decided 
characterize the epigenetic inactivation and its biological 
function of RPRM in BC cell lines.
MSP was performed on five BC cell lines, which revealed 
methylation of the promoter region of RPRM in 3/5 
(MDA-MB-231, BT-20 and HCC-1954) lines analyzed. 
However, qMSP analysis showed promoter methylation 
in 2/5 lines (MDA-MB-231 and BT-20; data not shown). 
These two lines exhibited loss or repression of RPRM 
mRNA expression. When we treated these cell lines with 
5′Aza-dC, mRNA expression was restored, indicating 
that methylation is the main mechanism of gene silencing 
of RPRM in the MDA-MB-231 and BT-20 cell lines. This 
phenomenon was also observed in esophageal adenocar-
cinoma and squamous carcinoma cell line OE33 and KYSE 
110 [21], respectively, and in three renal cell carcinoma cell 
lines (KTCL26, SKRC18 and SKRC39) [16]. Interestingly, 
RPRM is located at chromosome 2q23.3, a locus that often 
has allelic imbalance in BC [27]; nevertheless, we observed 
that loss or repression of mRNA expression was restored 
by 5′Aza-dC treatment, concluding that there is prob-
ably no allelic imbalance of 2q23 involved in loss of RPRM 
mRNA expression in these two cell lines.
Interestingly, only two cells lines (BT-20 and MDA-
MB-231) showed RPRM promoter methylation with 
mRNA expression loss, both of them ERα(−) cells. Sur-
prisingly, in ERα(+) cells MCF7 and T47D the RPRM 
promoter was hypomethylated and presented mRNA 
expression in contrast to ERα(+) BC tissues results, likely 
because cells culture are not being exposed to estrogen as 
BC tissues.
In functional studies, we tested whether RPRM could 
be less viable and increase PS translocation in MDA-
MB-231 cells, as previously reported in gonadotrope and 
GH pituitary cells [14]. However, there were no differ-
ences between cells with RPRM and the empty control. 
Also, we enquired as to whether RPRM could act as a 
G2/M phase cell cycle brake in MDA-MB-231 BC cells 
Fig. 2 mRNA expression and promoter methylation of RPRM in 
breast cancer cell lines. a Aberrant methylation was found in 3/5 of 
breast cancer cell lines studied. M methylated status, U unmethylated 
status. PCR product = 112 pb. b Expression levels before and after 
treatment with 5′‑Aza‑dC, by RT‑PCR. Cells were treated with 5′‑Aza‑
dC (5 μM) for 5 days. In two (MDA‑MB‑231 and BT‑20; lane 1 and 2, 
respectively) out of three BC cell lines the expression was decreased 
by methylation, and restored after 5′Aza‑dC treatment. RPRM PCR 
product = 137; 18S PCR product = 102 pb
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as previously reported in mouse embryonic fibroblast [6]. 
Unfortunately, RPRM cannot significantly alter G2/M in 
MDA-MB-231 cell line. Our results of cell cycle arrest are 
consistent with those in pituitary [14] and gastric tumors 
[15], suggesting that RPRM may perform an alterna-
tive cell function in non-fibroblast derived cells, or even 
depending on tumor type.
In addition, we examined whether RPRM has a role in 
cell migration and invasion. In an immunohistochemistry 
study involving S100A2 and RPRM, Luo et al. found that 
loss of RPRM protein expression was significantly corre-
lated with the depth of tumor invasion, lymphatic vessel 
invasion, and lymph node metastasis, suggesting tumor 
suppressor activity of RPRM in human clinical gastric 
tumor tissue [28]. In our study, we expressed RPRM 
ectopically in MDA-MB-231 cells, finding a significant 
decrease in cell migration by transwell inserts and wound 
healing as well as a significant decrease in cell invasion by 
inserts with matrigel, supporting an important role in cell 
mobility and invasion in MDA-MB-231 cells.
These results are not consistent with previous results 
about the biology of RPRM. However, a previous study by 
Song et al. into cyclin B1 (a protein target of RPRM) dem-
onstrated that, in addition to its known role in arresting 
the G2/M cell cycle phase, overexpression of cyclin B1 
in human esophageal squamous cell carcinoma (ESCC) 
promotes cell invasive growth and extravasation through 
the capillary endothelium. Furthermore, in xenograft 
Fig. 3 Effect of RPRM overexpression on migration and invasion properties in MDA‑MB‑231 cells. a qPCR and Western Blot of MDA‑MB‑231 cells 
with overexpression of RPRM (MDA‑MB‑231‑RPRM) and empty control (MDA‑MB‑231‑pCMV6). The antibody used was a monoclonal antibody 
anti‑DDK. Reprimo protein (12kD) is detected as 23–25 kD approximately due to glycosylation. b Overexpression of RPRM in MDA‑MB‑231 cells 
negatively regulates the migration ability. Representative micrographs of transwell migration assay were selected to show each condition (40× 
magnification). Quantification of cell migration expressed as the percentage of control. c Overexpression of RPRM in MDA‑MB‑231 reduced wound 
healing ability. Representative micrographs were taken at 0, 12, 24, 36 and 48 h (10× magnification). d Overexpression of RPRM in MDA‑MB‑231 
cells significantly reduced the invasion at 24 h using a matrigel‑coated insert. Representative images of invaded cells were selected to show each 
condition (40× magnification). Quantification of cell invasion expressed as the percentage of control. For each assay values were compared to 
control (MDA‑MB‑231‑pCMV6) using a Mann–Whitney test. The error bars indicate standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001
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mice, overexpression of cyclin B1 is able to enhance lung 
metastasis in ESCC. Likewise, suppression of endog-
enous cyclin B1 inhibits the metastatic potential of ESCC 
to the lung. In addition, cyclin B1-induced ESCC metas-
tasis appears to be linked to alteration of epithelial mes-
enchymal transition (EMT) molecules [7]. Given that 
RPRM regulates the activity of the Cdc2-cyclin B1 com-
plex, it is likely that the antagonist effect in cell migration 
and invasion is through cyclin B1 inactivation.
Conclusion
Our study was the first to report on the possible role 
of RPRM in the modulation of cell migration and inva-
sion process in  vitro in BC. Further investigation into 
the RPRM-regulated molecules is required, to clarify the 
mechanisms by which RPRM could exert tumor suppres-
sive activity in migration and invasion capability.
Methods
Cancer methylome system analysis
The CMS is a web-based database application designed 
for the visualization, comparison and statistical analy-
sis of human cancer-specific DNA methylation. The 
BC database was constructed with 77 breast tumors, 
10 normal breast samples (mammary reduction) 
and 41 BC cell lines. The datasets were obtained with 
the MBDCap-seq protocol, a technique used to cap-
ture methylated DNA by using a methyl-CpG binding 
domain (MBD) protein column followed by next-gen-
eration sequencing [25, 29]. We performed comparative 
analyses of DNA methylation profiles between nor-
mal controls and BC samples, which were downloaded 
from the CMS. Then, by computational analysis the 
average intensity correlation of methylation of RPRM 
CpG Island (1.1 kb length) was calculated in these two 
Fig. 4 Role of RPRM in cell death and cell cycle arrest in MDA‑MB‑231 cells. a Overexpression of RPRM in MDA‑MB‑231 cells did not decrease cell 
viability. b Ectopic expression of RPRM did not significantly increase cell death in MDA‑MB‑231 cells. c Modulating RPRM levels had no effect on 
progression of cell cycle phases. MDA‑MB‑231‑pCMV6 was used as a control. For each experiment, RPRM mRNA and protein levels were confirmed 
by qPCR and Western blot with an anti‑flag antibody, respectively
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groups. BC tissue samples were fresh frozen tissue with 
>70 % tumor cellularity.
Cell lines and transfections
BC cell lines MDA-MB-231, BT-20, T-47D, MCF7 and 
HCC1954 were generously provided by Dr. Tim Hui-
Ming Huang (University of Texas Health Science Center 
at San Antonio, TX). MDA-MB-231 and BT-20 were 
cultured in Dulbecco’s Modified Eagle’s medium (high 
glucose), T-47D and HCC1954 in Roswell Park Memo-
rial Institute (RPMI) 1640 medium (Thermo Scientific 
HyClone, Logan, UT, USA) and MCF7 in Advanced 
Modified Eagle’s medium (Invitrogen, Life Technolo-
gies corporation, Grand Island, NY, USA) supplemented 
with 10 % fetal bovine serum, 10 units/mL of penicillin 
and 10 mg/mL streptomycin (1 % penicillin/streptomy-
cin, Thermo Scientific Hyclone). All five cell lines were 
incubated at 37  °C in a humidified atmosphere con-
taining 5 % CO2 and subculture during the logarithmic 
phase.
To generate MDA-MB-231 transient-transfections, 
cells were transfected with pCMV6-RPRM-Myc-DDK-
tagged or pCMV6 (empty vector control) (OriGene 
Technologies, Inc), using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. All 
experiments were carried out in technical and biological 
triplicate. The success of transfection was confirmed by 
quantitative real-time PCR and western blot.
5′‑Aza‑2′‑deoxycytidine treatment
Breast cancer cell lines were incubated in culture medium 
with the demethylating agent 5-Aza-2′-deoxycytidine 
at a concentration of 5 μM for 5 days. Fresh media were 
added at 24 and 72 h. Cells were harvested and RNA was 
extracted at day 5 [16].
Real time PCR
Total cell RNA was isolated from cells using the TRIzol 
reagent (Life Technologies) according to the manufactur-
er’s instructions. First-strand cDNA was prepared from 
1 μg of cell RNA in a total reaction volume of 20 μL using 
M-MLV reverse transcriptase 200 U/μl (Promega Corp., 
Madison, WI) at 42  °C for 60 min. The resulting cDNA 
was subsequently amplified by PCR using the Brilliant II 
Ultra-Fast SYBR® Green qPCR Master Mix according to 
the manufacturer’s protocol on the Stratagene Mx-3000p 
real-time PCR system (Agilent Technologies Inc., Santa 
Clara, CA). Relative fold levels were determined using 
the 2−ΔΔCT method, with 18S used as housekeeping con-
trol. The primer pairs used are detailed in Table 1.
DNA extraction
Genomic DNA from cells was extracted using phenol/
chloroform and absolute ethanol DNA precipitation. The 
quantity and quality of extracted DNA were assessed by 
measuring the samples in a NanoDrop 1000 spectropho-
tometer (Thermo Fisher Scientific Inc., Waltham, MA).
Sodium bisulfite modification
A total of 1  μg of genomic DNA was modified with 
sodium bisulfite using the EZ DNA Methylation™ 
Bisulfite Kit (Zymo Research, Irvine, CA) following the 
manufacturer’s protocol. Bisulfite-converted DNA was 
stored at −80 °C until use.
Methylation‑specific PCR (MSP)
RPRM promoter was amplified from bisulfite-converted 
DNA using specific primers for methylated and unmeth-
ylated DNA, obtained from a previous report (Sato N 
et  al. [8]). Primer sequences and annealing tempera-
ture are provided in Table 1. Bisulfite-modified genomic 
Table 1 Primer and probe sequences used in this study
M methylated, U unmethylated
ID Sequences (5′–>3′) PCR product (pb) References
RPRM (forward) CTGCGAATTTGAACGGGGTGAGT 137 –
RPRM (reverse) GCGTAAACCGTGCAGTCACGA 137 –
RPRM‑M (forward) GCGAGTGAGCGTTTAGTTC 120 Sato et al. [8]
RPRM‑M (reverse) TACCTAAAACCGAATTCATCG 120 Sato et al. [8]
RPRM‑U (forward) TTGTGAGTGAGTGTTTAGTTTG 113 Sato et al. [8]
RPRM‑U (reverse) TAATTACCTAAAACCAAATTCATC 113 Sato et al. [8]
B‑actin‑M (forward) TGGTGATGGAGGAGGTTTAGTAAGT 133 Moon et al. [30]
B‑actin‑M (reverse) AACCAATAAAACCTACTCCTCCCTTAA 133 Moon et al. [30]
RPRM (probe qMSP) /56‑FAM/TT CGC GTC G/ZEN/T TCG CGG CGT TCG TT/3IABkFQ/ 120 –
B‑actin (probe qMSP) /56‑FAM/AC CAC CAC C/ZEN/C AAC ACA CAA TAA CAA ACA CA/3IABkFQ/ 133 Moon et al. [30]
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DNA was amplified by PCR, the cycle of which was: 
(a) 95 °C for 5 min; (b) 35 cycles: 95 °C 30 s, 59 °C 30 s, 
and 72 °C 30 s; (c) 72 °C 5 min for a final extension. As a 
positive control 100 % methylated DNA was used (Zymo 
Research, Irvine, CA). PCR mix without DNA was used 
as a blank. PCR products were analyzed by electrophore-
sis in 1.5 % agarose gel and visualized by gel red staining 
(Biotium, Hayward, CA) under UV light.
Quantitative methylation‑specific PCR (qMSP)
To quantify the methylation level of Reprimo, quantita-
tive methylation-specific PCR (qMSP) was performed. 
Amplification reactions were carried out in triplicate in a 
volume of 20 μL that contained 1 μL of bisulfite-modified 
DNA; 300  nM of each primer; 50  nM probe (Table  1); 
0.375  U platinum Taq polymerase (Invitrogen); 100  μM 
of dNTPs; 100  nM ROX dye reference (Invitrogen); 
8.3 mM ammonium sulfate; 33.5 mM Trizma (Sigma, St. 
Louis, MO); 3.35 mM magnesium chloride; 5 mM mer-
captoethanol; and 0.05  % DMSO [30]. Amplifications 
were carried out using the following profile: 95  °C for 
10 min followed by 40 cycles at 95 °C for 30 s, 59 °C for 
30 s and 72 °C for 30 s. Amplification reactions were car-
ried out in 96-well plates in the Mx3000P QPCR System 
(Stratagene). Each plate included DNA samples, positive 
control (100  % methylated DNA, Zymo Research) and 
water blanks. The relative level of methylated DNA for 
RPRM was determined as a ratio of methylation-specific 
PCR-amplified gene to β-actin (reference gene) and then 
multiplied by 1000 for easier tabulation (average value of 
triplicates of the study gene divided by the average value 
of triplicates of β-actin × 1000) [30, 31].
Western blot
2 × 105 MDA-MB-231 cells were transiently transfected 
with pCMV6-RPRM-Myc-DDK-tagged or pCMV6 
(empty vector control) (OriGene Technologies, Inc), 
using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. Cells were harvested 
and whole-cell lysates were extracted using RIPA buffer 
(50 mM Tris, pH 7.2; 150 mM NaCl; 1 % Triton X-100; 
and 0.1 % SDS).
With Protease and Phosphatase Inhibitor Cock-
tail Kit (Sigma Aldrich). Protein concentrations were 
determined using Pierce BCA protein assay kit (Pierce, 
Thermo Fisher Scientific Inc, Rockford, IL, USA) accord-
ing to the manufacturer’s instructions. Equal amounts of 
total cellular protein (40  μg) were separated by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis in 
4–12  % NuPAGE® Bis–Tris Precast Gels (Novex, Life 
Technologies Corporation) and electrotransferred to 
polyvinylidene difluoride membranes (Immobilon®-P 
membrane, Millipore, Bedford, MA, USA). The 
membranes were blocked with 1 ×  Tris-buffered saline 
containing 0.05 % Tween (TBST) and 5 % fat-free milk for 
1  h at room temperature. Primary antibodies anti-DDK 
(Origene technologies; cat. Nº TA50011) and anti β-actin 
(Cell Signalling; cat.Nº 13E5) were diluted 1:2,000 and 
1:5,000, respectively, in TBST/3 % BSA, the membranes 
were incubated in primary antibodies at 4  °C overnight. 
The Membranes were washed three times in TBST for 
10  min. Both anti-mouse and anti-rabbit peroxidase-
conjugated secondary antibody (Santa Cruz) were diluted 
in 1:20,000 in TBST 1X and incubates the membrane for 
1 h at room temperature. The membranes were washed 
as above and visualized using SuperSignal West Pico 
(Pierce) according to the manufacturer’s protocol.
Viability assays
Cell viability in transfected MDA-MB-231 cells was 
determined using the CellTiter 96 AQueous one solu-
tion (Promega). Five thousand MDA-MB-231cells were 
seeded in a 96-well plate (four replicates for each condi-
tion) and allowed to attach overnight. Transfection was 
performed 24 h later, using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. Cells 
were incubated for 24, 48 and 72  h after transfection. 
Control wells contained only cell-free medium. Twenty 
microliters of CellTiter MTS solution were added to each 
well, and plates were incubated for 1 h at 37 °C. Absorb-
ance was measured at 490 nm.
Apoptosis analysis
To study cell death from within transfected MDA-MB-231 
cells to the outer leaflet of the plasma membrane, we used 
the Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit 
(Life Technologies), staining according to the manufac-
turer’s instructions, and analyzed it by flow cytometer 
(FACs Canto II, Becton–Dickinson). A total of 2.5 × 105 
MDA-MB-231 cells were plated in a 6-multiwell plate (two 
replicates of each condition) and allowed to attach over-
night. Transfection was performed 24 h later, using Lipo-
fectamine® 2000 (Invitrogen) following the manufacturer’s 
protocol. Cells were incubated for 48 h post-transfection. 
Positive control cells were treated with 5  % DMSO for 
24 h. Wild-type cells were used as a negative control.
Cell cycle analysis
MDA-MB-231 (2.5 × 105 cells per well) cells were plated 
in a 6-multiwell plate (two replicates of each condi-
tion) and allowed to attach overnight. Cells were syn-
chronized by starvation in serum-free media for 24  h. 
Immediately, transient transfection was performed using 
Lipofectamine® 2000 (Invitrogen). Cells were incubated 
for 48 h post-transfection in complete media. After incu-
bation period, the cells were trypsinized, re-suspended, 
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fixed (ethanol 70 % for 2 h at 4 °C) and finally stained with 
PI solution (0.1  % (v/v) Triton X-100, 10  μg/mL PI, and 
100 ug/mL DNase-free RNase A in PBS). Cell cycle pro-
files were gathered using a Flow cytometer (FACs Canto II, 
Becton–Dickinson) at the Universidad de La Frontera Sci-
entific and Technological Bioresource Nucleus (BIOREN).
Cell migration
A total of 5  ×  104 transient MDA-MB-231 transfected 
cells were suspended in 300  μl of serum-free DMEM 
medium and seeded into the upper chamber of each 
insert (24-well insert; pore size, 8  μm; BD Biosciences). 
Then, 500 μL of DMEM containing 10 % FBS were added 
to a 24-well plate. After incubation at 37  °C for 12  h, 
migrated cells were washed (twice with DPBS), fixed 
(Methanol 100 %) and stained for 15 min in crystal vio-
let solution (0.5 % crystal violet in 25 % methanol/DPBS). 
Cells that did not migrate to the lower compartment 
were removed with a cotton swab. Each insert was photo-
graphed in five random fields at a magnification of 40×. 
Quantification is expressed as the percentage of area 
covered with migrated cells by using ImageJ software 
(Wayne Rasband, National Institute of Health, USA).
Wound healing
A total of 1 × 105 MDA-MB-231 cells were plated in a 24 
multi-well plate. Transient transfection was performed 
after 24 h. Cells were allowed to form a confluent mon-
olayer in a 24-well plate before wounding. A sterilized 
pipette tip was used to generate wounding across the cell 
monolayer, and the debris was washed with PBS. Cells 
migrating into the wounded area were visualized and pho-
tographed under an inverted microscope at varying inter-
vals. A total of six areas were selected randomly in each 
condition and photographed at a magnification of 10×.
Cell invasion
MDA-MB-231 cells were transfected with pCMV6-RPRM 
or pCMV6 vector using Lipofectamine 2000 (Invitrogen), 
following the manufacturer’s protocol. Serum-induced 
cell invasion were performed at 37  °C for 24  h using a 
24-well transwell insert (24-well insert; pore size, 8  μm; 
BD Biosciences) coated with 30  μg of matrigel (BD Bio-
sciences). 5  ×  104 cells suspended in 200  μl serum-free 
medium were seeded into the upper chamber and 600 μl 
complete medium into the lower chamber. After 24 h, the 
upper surface of the insert was wiped gently with a cotton 
swab to remove non-migrating cells. Cells that migrated 
and invaded through the membrane were stained with 
crystal violet solution (0.5 % crystal violet in 25 % metha-
nol/DPBS), and photographed by a microscope with a 
camera in five random fields at a magnification of 40×. 
Quantification is expressed as the percentage of area 
covered with migrated cells by using ImageJ software 
(Wayne Rasband, National Institute of Health, USA).
Statistical analysis
Data were analyzed by a Mann–Whitney test, Kruskal–
Wallis test and two-way ANOVA with Bonferroni’s mul-
tiple comparisons test using GraphPad Prism software 
(San Diego, CA). Values were expressed as mean ±  SD. 
Values of P < 0.05 were considered statistically significant.
Additional data
The data supporting the result about RPRM meth-
ylation in BC tissues and cell lines were obtained from 
CMS website available in http://cbbiweb.uthscsa.edu/
KMethylomes/.
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